Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Declines By 16.2%

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 921,900 shares, a decline of 16.2% from the November 15th total of 1,100,000 shares. Based on an average daily volume of 840,800 shares, the days-to-cover ratio is currently 1.1 days.

BioLineRx Price Performance

BLRX remained flat at $0.22 during midday trading on Friday. The company’s stock had a trading volume of 973,980 shares, compared to its average volume of 493,844. BioLineRx has a fifty-two week low of $0.21 and a fifty-two week high of $1.77. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The firm has a 50 day moving average price of $0.39 and a two-hundred day moving average price of $0.57. The company has a market cap of $17.98 million, a PE ratio of -1.02 and a beta of 1.39.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BLRX. PVG Asset Management Corp bought a new stake in shares of BioLineRx during the 2nd quarter valued at about $70,000. CVI Holdings LLC bought a new position in BioLineRx in the second quarter worth about $462,000. Finally, Atria Investments Inc lifted its holdings in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the period. 1.56% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BLRX. HC Wainwright cut their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th. StockNews.com assumed coverage on shares of BioLineRx in a report on Tuesday. They issued a “hold” rating on the stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.